Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2018

01-03-2018 | review

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood

Authors: Edit Bardi, MD, Ph.D, Assoc. Prof. Leo Kager, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2018

Login to get access

Summary

Survival after childhood cancer has improved substantially; therefore, the number of childhood cancer survivors is increasing. This growing population of childhood cancer survivors, however, is at risk of a spectrum of adverse health outcomes. Unfortunately, until now, there was a lack of comprehensive follow-up recommendations. The purpose of this article is to provide information on recently developed harmonized evidence-based guidelines on surveillance investigations to screen for the early detection of breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian failure in childhood cancer survivors. We point out the need for a multidisciplinary pediatric and adult specialist team, who together develop multidisciplinary long-term follow-up clinics.
Literature
1.
Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):35–47.CrossRefPubMed
2.
3.
4.
Madanat-Harjuoja LM, Pokhrel A, Kivivouri SM, Saarinen-Pihkala UM. Childhood cancer survival in Finland (1953–2010): a nation-wide population-based study. Int J Cancer. 2014;135(9):2129–34.CrossRefPubMed
5.
Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer. 2009;45(6):992–1005.CrossRefPubMed
6.
Vassal G, Fitzgerald E, Schrappe M, et al. Challenges for children and adolescents with cancer in europe: the SIOP-europe agenda. Pediatr Blood Cancer. 2014;61(9):1551–7.CrossRefPubMed
7.
Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.CrossRefPubMed
8.
Hjorth L, Haup R, Skinner R, et al. Survivorship after childhood cancer: pancare: a European network to promote optimal long-term care. Eur J Cancer. 2015;51(10):1203–11.CrossRefPubMed
9.
Kremer LCM, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60:543–9.CrossRefPubMed
10.
Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444–55.CrossRefPubMedPubMedCentral
11.
12.
Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217–23.CrossRefPubMedPubMedCentral
13.
Mulder RL, Kremer LC, Hudson MM, et al. Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2013;14(13):e621–e9.CrossRefPubMedPubMedCentral
14.
American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular Radiolo, Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927–95.CrossRef
15.
Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44:600–6.CrossRefPubMed
16.
Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.CrossRefPubMedPubMedCentral
17.
Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–e36.CrossRefPubMedPubMedCentral
18.
Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5‑year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328–38.CrossRefPubMedPubMedCentral
19.
Skinner R, Mulder RL, Kremer LC, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Lancet Oncol. 2017;18(2):e75–e90.CrossRefPubMed
20.
van Dorp W, Mulder RL, Kremer LC, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the pancareSurFup consortium. J Clin Oncol. 2016;34(28):3440–50.CrossRefPubMedPubMedCentral
21.
McCabe MS, Partridge AH, Grunfeld E, Hudson MM. Risk-based health care, the cancer survivor, the oncologist, and the primary care physician. Semin Oncol. 2013;40(6):804–12.CrossRefPubMedPubMedCentral
22.
Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academies Press; 2006.
23.
Hewitt M, Weiner SL, Simone JV. Childhood cancer survivorship: improving care and quality of life. Washington, D.C.: The National Academies Press; 2003.
Metadata
Title
Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood
Authors
Edit Bardi, MD, Ph.D
Assoc. Prof. Leo Kager, MD
Publication date
01-03-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0387-z

Other articles of this Issue 1/2018

memo - Magazine of European Medical Oncology 1/2018 Go to the issue

case report

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity

editorial

My burning issues in TKI therapy and treatment-free remission in CML

editorial

memo—publisher’s report 2017

short review

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

review

My burning issues in the neoadjuvant treatment for breast cancer

case report

Local therapy of stage IV renal cell cancer: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits